Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Gynocare cost action ca18117 “European network for gynaecological rare cancer research : from concept to cure”

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Publication Information:
      Grupo Saned
    • Publication Date:
      2023
    • Collection:
      University of Malta: OAR@UM / L-Università ta' Malta
    • Abstract:
      Introduction: Up to 50% of all gynecologic tumors can be classified as rare (incidence of < 6 per 100,000 women) and usually have a poor prognosis owing to delayed diagnosis and treatment. Contrary to other common solid tumors, the treatment of rare gynecologic tumors (RGT) is often based on retrospective studies, expert opinion or extrapolation from other tumor sites with similar histology, leading to difficulty in developing guidelines for clinical practice. Currently, gynecologic cancer research, due to distinct scientific and technological challenges, is lagging behind. Moreover, the overall efforts for addressing these challenges are fragmented across different European countries and indeed, worldwide. Aims: GYNOCARE is an EU funded programme that aims to address these challenges by creating a unique network between key stakeholders covering distinct RGT research areas ranging from concept to cure: basic research, biobanking, bridging with industry, and setting up the legal and regulatory requirements for international innovative clinical trials. Methods: To achieve these ambitious goals, GYNOCARE focuses on (1) capacity-building on rare gynaecological cancer by connecting high-quality scientific communities in various disciplines, existing networks, policy-makers, industrial partners, and patient organisations across Europe and beyond; (2) coordinating, and contributing to the development of a research roadmap dedicated to connect (innovative) basic research to (harmonised) biobanking to ‘smarter’ clinical trials; (3) the development of a platform for sharing best practices, including funding roadmap and legal/ethical requirements, in gynaecological cancers – aiming to advice policy-makers and other key stakeholders; and (4) providing (equal) networking opportunities for early-stage researchers, and other talented young professionals. Results: Over 50 members from 20 countries form part of the GYNOCARE Consortium. Conclusion: This COST Action is an effective tool in order to bring together different key ...
    • ISSN:
      15767965
    • Relation:
      https://www.um.edu.mt/library/oar/handle/123456789/113750
    • Accession Number:
      10.1016/j.ejogrb.2021.11.150
    • Online Access:
      https://www.um.edu.mt/library/oar/handle/123456789/113750
      https://doi.org/10.1016/j.ejogrb.2021.11.150
    • Rights:
      info:eu-repo/semantics/openAccess ; The copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder.
    • Accession Number:
      edsbas.6E4E2ECE